Skip to main content
. 2022 Nov 10;23(22):13873. doi: 10.3390/ijms232213873
UBE2C ubiquitin-conjugating enzyme 2C
PCa prostate cancer
AR androgen receptor
ADT androgen-deprivation therapy
mCRPC metastatic castration-resistant prostate cancer
NMF non-negative matrix factorization
RFS recurrence-free survival
UPP ubiquitin–proteasome proteolytic